Related Experiment Video
Updated: Apr 13, 2026
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Treatment outcome and its attributes in TB-HIV co-infected patients registered under Revised National TB Control
N N Ambadekar1, S P Zodpey2, R N Soni3
1Dept of Public Health, Akola, Maharashtra, India.
Objectives:
DOTS treatment has shown to be effective in TB patients with or without HIV infection although there have been some conflicting evidence. This may be due to various factors associated with HIV-TB co-infection and its treatment. Thus the present study was planned to study the outcome of DOTS and factors associated with same in TB-HIV co-infected patients.
Study Design:
A retrospective cohort analysis was done.
Methods:
886 TB-HIV co-infected patients who were registered under RNTCP were the subjects. Data from RNTCP was obtained on diagnosis of TB, HIV and TB therapy and some attributes.
Results:
Average cure rate for NSP TB-HIV co-infected patients was 72% compared with 83% of total NSP registered patients (P < 0.001). Death rate in NSP TB-HIV co-infected patients was 16% (P < 0.001). In non-NSP TB-HIV co-infected patients, success rate was 80%. Death rate was significantly higher i.e. 12% in non-NSP TB-HIV co-infected cases as compared with 6% in total registered patients. Death rate was 19% in RT TB-HIV co-infected patients while 11% in all registered RT cases (P < 0.001). In TB-HIV co-infected patients paediatric patients, patients with extra pulmonary TB and new patients without any history of previous treatment had a higher chance of success at treatment. Patients with Pulmonary TB had higher chance of death.
Conclusion:
Success rate was significantly lower and death rate was significantly higher among the TB-HIV co-infected cohort with age, type of TB and history of previous treatment affecting the success rate of treatment and type of TB affecting the death rate.
More Related Videos
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:10Retrovirus Life Cycles